These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 29273427)
1. Patients lacking glycemic control place more burdens on health services with the use of medications. Camargos AMT; Gonçalves ACO; Cazarim MS; Sanches C; Pereira LRL; Baldoni AO Diabetes Metab Syndr; 2018 May; 12(3):279-283. PubMed ID: 29273427 [TBL] [Abstract][Full Text] [Related]
2. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Bahia LR; Araujo DV; Schaan BD; Dib SA; Negrato CA; Leão MP; Ramos AJ; Forti AC; Gomes MB; Foss MC; Monteiro RA; Sartorelli D; Franco LJ Value Health; 2011; 14(5 Suppl 1):S137-40. PubMed ID: 21839888 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of a pharmacotherapeutic empowerment strategy for patients with type 2 diabetes mellitus. Gonçalves ACO; Cazarim MS; Sanches C; Pereira LRL; Camargos AMT; Aquino JA; Oliveira Baldoni A BMJ Open Diabetes Res Care; 2019; 7(1):e000647. PubMed ID: 31413839 [TBL] [Abstract][Full Text] [Related]
5. Association of good glycemic control and cost of diabetes care: Experience from a tertiary care hospital in Bangladesh. Afroz A; Chowdhury HA; Shahjahan M; Hafez MA; Hassan MN; Ali L Diabetes Res Clin Pract; 2016 Oct; 120():142-8. PubMed ID: 27552073 [TBL] [Abstract][Full Text] [Related]
6. Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. Foos V; Varol N; Curtis BH; Boye KS; Grant D; Palmer JL; McEwan P J Med Econ; 2015 Jun; 18(6):420-32. PubMed ID: 25629654 [TBL] [Abstract][Full Text] [Related]
7. Heart failure is associated with non-adherence to pharmacotherapy in elderly with type 2 diabetes mellitus in public health system Brazilians. Peres HA; Leira Pereira LR; Martinez EZ; Viana CM; Foss-Freitas MC Diabetes Metab Syndr; 2019; 13(2):939-946. PubMed ID: 31336548 [TBL] [Abstract][Full Text] [Related]
8. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004. van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664 [TBL] [Abstract][Full Text] [Related]
9. State of diabetes care in the United States. Blonde L Am J Manag Care; 2007 Apr; 13 Suppl 2():S36-40. PubMed ID: 17417931 [TBL] [Abstract][Full Text] [Related]
10. Clinical and economic outcomes associated with National Kidney Foundation guideline-concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease. Chen SY; Siu K; Kovacs B; Stokes M; Rao P; Sander S; Boulanger L Curr Med Res Opin; 2012 Apr; 28(4):493-501. PubMed ID: 22364567 [TBL] [Abstract][Full Text] [Related]
11. Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania. Domeikienė A; Vaivadaitė J; Ivanauskienė R; Padaiga Ž Medicina (Kaunas); 2014; 50(1):54-60. PubMed ID: 25060205 [TBL] [Abstract][Full Text] [Related]
12. A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. de Groot S; Enters-Weijnen CF; Geelhoed-Duijvestijn PH; Kanters TA BMJ Open; 2018 Mar; 8(3):e019864. PubMed ID: 29581204 [TBL] [Abstract][Full Text] [Related]
13. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting. Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912 [TBL] [Abstract][Full Text] [Related]
14. Role of Devices in Insulin Delivery. Meneghini LF; McNulty JN Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052 [No Abstract] [Full Text] [Related]
15. Managing type 2 diabetes: going beyond glycemic control. Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582 [TBL] [Abstract][Full Text] [Related]
16. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. Xie L; Wei W; Pan C; Baser O J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434 [TBL] [Abstract][Full Text] [Related]
17. The cost of managing severe hypoglycemic episodes in Type 2 diabetic patients. Laires PA; Conceição J; Araújo F; Dores J; Silva C; Radican L; Nogueira A Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):315-25. PubMed ID: 26844705 [TBL] [Abstract][Full Text] [Related]
18. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus. Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013 [TBL] [Abstract][Full Text] [Related]
19. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis. Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233 [TBL] [Abstract][Full Text] [Related]
20. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]